1. msrobins66
2. nevadawriter
3. 49363
1.nevadawriter 07/09/2018
Spero Therapeutics Announces Proposed Offering of Common Stock
2.msrobins66 07/16/2018
Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
3.49363 05/24/2018
Cantor Fitzgerald sets PT at $27
4.nevadawriter 05/24/2018
Announces results from the Company’s Phase 1b drug-drug interaction trial of SPR741
5.nevadawriter 02/08/2018
Cantor Fitzgerald initiates coverage with Overweight rating, $27 PT
6.msrobins66 04/16/2018
Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW